SLC16A1 and glioblastoma: Given that tumor cells can export pyruvate to microenvironment via monocarboxylate transporter 1 (MCT1), we have reason to believe that tumor cells with high levels of pyruvate could promote the resistance of neighbor tumor cells to DNA damage by the paracrine mechanism, thereby implicating the therapeutic opportunity of lowering intracellular pyruvate levels by pharmacological inhibition to increase the efficacy of current therapeutics for glioblastoma.